Drugs / MTX
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT07153796 Background | Jan 2026 → Sep 2031 expected | B-cell acute lymphoblastic leukemia | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MTX | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07153796 ↗ |